Nutritional management of growth faltering in infants aged under six months in Asia and Africa. Study protocol for an individually randomised trial... (Projects)
https://www.swisstph.ch/en/projects/project-detail/project/nutritional-management-of-growth-faltering-in-infants-aged-under-six-months-in-asia-and-africa-study-protocol-for-an-individually-randomised-trial-branch
The WHO Department of Maternal, Newborn, Child and Adolescent Health and Ageing (WHO/MCA) will coordinate a multi-country, multi-centre randomised controlled trial to evaluate the effect of approaches
Support for the launch of calls for project proposals against neglected tropical diseases in Benin and Togo (Projects)
https://www.swisstph.ch/en/projects/project-detail/project/support-for-the-launch-of-calls-for-project-proposals-against-neglected-tropical-diseases-in-benin-and-togo
The raison d’être of Anesvad is to improve the health of the most neglected people and communities. A major ongoing quest is the fight against neglected tropical diseases (NTDs) with a focus on skin N
Technical Assistance to Country-Led Evaluations Supported by the Global Financing Facility & Metareview of Evidence (Projects)
https://www.swisstph.ch/en/projects/project-detail/project/technical-assistance-to-country-led-evaluations-supported-by-the-global-financing-facility-metareview-of-evidence
Swiss TPH provides technical assistance to country organisations currently engaged in the implementation of Global Financing Facility (GFF) Investment Case (IC) evaluations, with the aim to strengthen
Literature review on the progress of the 2018 Vaccine Investment Strategy (VIS) (Projects)
https://www.swisstph.ch/en/projects/project-detail/project/literature-review-on-the-progress-of-the-2018-vaccine-investment-strategy-vis
In 2018, the Gavi Board approved the inclusion of Rabies Post-Exposure Prophylaxis (PEP) into the portfolio of vaccines to be funded in the 2021-2025 strategic period. Various challenges were identifi
Clinical Performance Evaluation and Cost-Effectiveness Analysis of miLab platform for Supporting Malaria Control in Target Countries (Projects)
https://www.swisstph.ch/en/projects/project-detail/project/clinical-performance-evaluation-and-cost-effectiveness-analysis-of-milab-platform-for-supporting-malaria-control-in-target-countries
Noul Inc, a South Korean start-up, has developed the miLab(TM) platform, which allows automated sample preparation to imaging and AI analysis of small amounts of blood samples. The platform is of pote
Characterization of field malaria isolates and assessment of the impact of resistance profile on the transmission of resistant strains (Projects)
https://www.swisstph.ch/en/projects/project-detail/project/characterization-of-field-malaria-isolates-and-assessment-of-the-impact-of-resistance-profile-on-the-transmission-of-resistant-strains
This is a joint research project between Swiss Tropical and Public Health Institute (SwissTPH, Switzerland) and Ifakara Health Institute (IHI, Tanzania). Malaria elimination is threatened by resistanc
Controlled Temperature Chain Research Study on HPV in Côte d'Ivoire (Projects)
https://www.swisstph.ch/en/projects/project-detail/project/controlled-temperature-chain-research-study-on-hpv-in-cote-divoire
The Vaccine Innovation Prioritization Strategy (VIPS) goal is to provide greater clarity on lower- and middle-income country (LMIC) needs to manufacturers as well as partners to inform and influence i
Swiss TPH Strategy 2025-2028 (Projects)
https://www.swisstph.ch/en/projects/project-detail/project/swiss-tph-strategy-2025-2028
The Swiss TPH Strategy 2025-2028 is based on SERI's funding phase and is further developed in line with it every four years. The four-year goals, developed in a participatory manner and with the invol
Studying the evolution of Mycobacterium tuberculosis across timescales and its consequences for drug resistance development and patient treatment... (Projects)
https://www.swisstph.ch/en/projects/project-detail/project/studying-the-evolution-of-mycobacterium-tuberculosis-across-timescales-and-its-consequences-for-drug-resistance-development-and-patient-treatment-outcomes
Tuberculosis (TB) remains one of the most important global health problems. With the COVID-19 pandemic receding, TB is once again the number one cause of human mortality due to infection. Moreover, mu
HIV/AIDS Prevention in Central Africa, Phase VI (Projects)
https://www.swisstph.ch/en/projects/project-detail/project/hiv/aids-prevention-in-central-africa-phase-vi
Based on the results of the previous phases, Phase VI of the Projet Prévention VIH/SIDA en Afrique Centrale (PPSAC) emphasizes continuity, but at the same time refocus certain main lines of activity.